A new Ebola drug grown from special tobacco plants has been shown to cure monkeys that were already displaying signs of infection by the viral hemorrhagic fever, the Los Angeles Times reported on Wednesday.
Other Ebola countermeasures have been shown to work on infected animals before they start displaying symptoms of the highly virulent and lethal disease. However, this is the first time a drug has demonstrated any effectiveness after signs of the virus have manifested. That is regarded as a crucial capability in the event of a real-life disease epidemic, according to virologist Gene Olinger, who works at the Army Medical Research Institute of Infectious Diseases at Fort Detrick, Md.
“We’ve pushed the opportunity to treat people to the point where they walk in and say, ‘I have a fever,’” said Olinger, co-author of a report on the new Ebola drug published by the Science Translational Medicine journal on Wednesday. “A lot of folks in the field would have thought protecting an animal at the time of fever and viremia is too late to have a clinical benefit.”
Ebola is one of the most deadly and contagious diseases known to exist in nature. The lack of adequate vaccines and antidotes for the disease have made it a serious worry for biodefense specialists concerned about its possible applications as a biological weapon.
In the recent study, seven infected rhesus monkeys were administered the experimental treatment MB-003 through their veins once every three days. Three of the monkeys did not die, resulting in a statistically notable success rate of 43 percent.
Fort Detrick scientist and lead study author James Pettitt said it is probable that in a real-life outbreak, the drug would be administered at a higher dosage and with greater frequency.
“We think we’ll get better results,” the researcher said.
Growing the drug from specially developed tobacco leaves is not only less costly than conventional cell-based methods, but also allows for large batches of the drug to be produced on fairly short, weeklong schedules, according to the Times article.
Olinger said further measures will be taken to improve MB-003 by adding to it more Ebola antibodies that were discovered by a different group of researchers.
- 1 How Ron Wyden Banned Internet Taxes Forever
- 2 Obama’s Second-Term Agenda Hits a Roadblock: the Supreme Court
- 3 John Kasich Dismisses Climate Change As ‘Some Theory That’s Not Proven’
- 4 Obamacare Will Reduce Income Inequality, but Quietly
- 5 I Did Improv With the ‘Jeopardy Villain,’ and He’s Exactly as He Appears on Television
What We're Following See More »
Under pressure from a judge, the State Department will release about 550 of Hillary Clinton’s emails—“roughly 14 percent of the 3,700 remaining Clinton emails—on Saturday, in the middle of the Presidents Day holiday weekend.” All of the emails were supposed to have been released last month. Related: State subpoenaed the Clinton Foundation last year, which brings the total number of current Clinton investigations to four, says the Daily Caller.
UPDATED: Sen. Jim Webb (D-VA) will not be playing the role of Ralph Nader in this year’s election. Speaking in Dallas today, Webb said, “We looked at the possibility of an independent candidacy. Theoretically, it could be done, but it is enormously costly and time sensitive, and I don’t see the fundraising trajectory where we could make a realistic run.”
“The leaders of the Republican and Democratic national committees on Wednesday weighed in on the prospect of an independent presidential run by” former New York City Mayor Michael Bloomberg (I). “DNC Chairwoman Debbie Wasserman Schultz suggested that the former New York City mayor’s priorities are already ‘well cared-for’ in the Democratic platform, while RNC leader Reince Priebus welcomed the idea, saying Bloomberg would siphon off votes from the Democratic candidate.”
Three hundred fifty-two, thanks to superdelegates pledged to Clinton, and the vagaries of the delegate allocation process in early states. Not bad, considering her results have been a virtual tie and a blowout loss.